Higher dementia risk classification

1. Semaglutide decreases higher dementia risk classification in humans (36% lower odds, β -0.44, P < 0.001).

   Human trialoverweight/obesity and cardiovascular disease without diabetes2.4 mg104 weeksn = 2,970

   Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial

   Alzheimer's & dementia (Amsterdam, Netherlands)·8 Aug 2026

More on Semaglutide